Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
03:59p CITIGROUP : Citi Report Highlights Strong Investor Interest in Depositary Receipts in the First Half of 2015
03:58p RESEARCH AND MARKETS : Hydropower in China, Market Outlook to 2025 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles
03:56p RESEARCH AND MARKETS : Cutaneous Mastocytosis Pipeline Insights Report 2015
03:54p WAL MART STORES : Police Log ; Disorderly Conduct Retail Theft Vehicle Crash Warrant
03:54p GOLDMAN SACHS : Hedge Fund Manager Known For Inspiring Spine-Tingling Terror In People Hopes To Lighten Things Up With Haunted House Come October
03:54p PPL : Talen Spinoff Triggers Q2 Loss Of $757M
03:54p First National Gets Ok To Buy Bank Of America
03:54p UNILEVER : Values-Led Sourcing Can Make A Difference Here
03:54p BREITLING ENERGY : Regulation FD Disclosure (form 8-K)
03:54pDJJudge Reinstates ATM Antitrust Case Against Visa, MasterCard
Latest news
Advertisement
Hot News 
MOLYCORP : Japan June Rare Earth Import Up 70%
MIRLAND DEVELOPMENT : Says Russian Portfolio To Drop In Value In Second Quarter
METRO BANCORP : F.N.B. Corporation : Expands Central Pennsylvania Presence with the Acquisition of Metro Bancorp, Inc.
THERAMETRICS : SIX: TMX) announces today that it has completed the acquisition of 38,500,000 of its own shares from its shareholders Pierrel S.p.A. and Fin Posillipo S.p.A.
TRINET : reports 2Q loss
Most Read News
08/03 CENTER FOR INFECTIOUS DISEASE RESEARCH : Launches “Become the Cure” Bumbershoot Ticket Raffle
02:42p Apple and interest rate jitters weigh on Wall Street
08/03 WIDE KATE LENS UP-DIP INTERCEPT : 34.0m @ 20.8% ZnEq
12:37p Earnings-day blues, Shire bid leave UK shares flat
08/03 WIDE KATE LENS UP-DIP INTERCEPT : 34.0m @ 20.8% ZnEq
Most recommended articles
03:54pDJJudge Reinstates ATM Antitrust Case Against Visa, MasterCard
03:51pDJKellogg Profit Falls 24% as Currency Dents Sales -- Update
03:45pDJSEC Set to Approve CEO Pay-Gap Disclosure Rule
03:45pDJU.S. Auto Leasing on Track to Return to 1999 Levels
03:39pDJUSDA Chicago Terminal Grain - Aug 4